stryker

Stryker Corporation (NYSE: SYK) announced on Wednesday that it has entered into a definitive agreement to acquire all of the assets associated with Synergetics USA's neuro portfolio. As part of the agreement, Stryker will acquire Synergetics' portfolio which includes the Malis generator...

Stryker Corporation (NYSE: SYK), a leading medical technology company, announced on Monday it will acquire Sage Products, LLC from Madison Dearborn Partners for $2.775 billion in cash. Shares of Stryker were trading lower by 0.56 percent at $98.59 mid-Monday afternoon. Sage is a developer of...

Here's a quick look at some of the top performing health care stocks, year to date. These stocks all have a market cap of more than $1 billion and all pay a dividend. Baxter International (NYSE: BAX) is more than 11% higher than a month ago, and more than 17% higher than a year ago. The company...

J.P. Morgan is out with its report today on Stryker (NYSE: SYK), reiterating Neutral. In a note to clients, J.P. Morgan writes, "Stryker reported a 2Q result that was mostly in line, with sales of $2,046M (+16.3%, +5.7% organic) coming in about $40M above Street consensus, reflecting a...

Stryker's (NYSE: SYK) 1Q knee results across the board were down from 4Q, Jefferies reports. “The worldwide market was flat and U.S. was down 4%; sequentially, U.S. was 500bp slower,” Jefferies writes. “It is a bit confounding that knees decelerated so precipitously in 1Q given that several...

Deutsche Bank is out with its report today on Stryker (NYSE: SYK), maintaining Hold. In a note to clients, Deutsche Bank writes, "Hill-Rom (NYSE: HRC) hosted an investor day on Tuesday providing its long-range plan and views on the market HRC competes with Stryker's Medical franchise (8% of total...

According to Deutsche Bank, Stryker (NYSE: SYK) hasn't stopped believing in diversification. Deutsche Bank said that mgmt reiterates guidance and positive outlook at investor day. “At its investor meeting, Stryker reiterated its financial guidance and gave an upbeat view of its strategy (...

Goldman Sachs reiterated its Buy rating on Stryker (NYSE: SYK) after attending its annual investor meeting. At the same time, Goldman increased its price target from $71 to $73. In a research report published today, Goldman stressed its optimism about Stryker's launching of new products, as well as...

Goldman Sachs is upgrading shares of Becton, Dickinson and Company (NYSE: BDX) and Stryker Corp. (NYSE: SYK) to Buy. Stryker closed Tuesday at $61.00; Becton, Dickinson and Company closed at $87.75.

In a report released this morning, Jefferies said that its Stryker Corp. (NYSE: SYK) estimates remain within guidance. “The full year guidance was kept at constant currency revenue growth of 11% to 13% (+5% to 7% ex-acquisitions) and adjusted EPS of $3.65 to $3.73,” Jefferies writes. “The EPS...

JP Morgan has published a research report on Stryker Corporation (NYSE: SYK) after the company reported positive 4Q10 earnings results on Monday. In the report, JP Morgan writes "Stryker expects total 4Q revenues to come in at $1.995B (+8.8%), a full $50M above consensus and $30M ahead of our own $...

Stryker (NYSE: SYK) announced yesterday a definitive agreement to sell its OP-1 bone morphogenetic protein (BMP) family of products for orthopedic applications to Olympus Corporation for $60M. This isn't a surprising move considering the clinical struggles SYK has had with OP-1 in orthopedic...

Oppenheimer is out with its research report on Stryker, (NYSE: SYK)after SYK announced it will sell off its OP-1 BMP products to Olympus Corp. for $60 million. In a note to clients, Oppenheimer writes, "This isn't a surprising move considering the clinical struggles SYK has had with OP-1 in...

Stryker Corporation (NYSE: SYK) does not expect the sale to impact EPS guidance for 2010, which is expected to be in the range of $3.27 to $3.30, Jefferies reports. “The company did not comment on sales guidance,” Jefferies writes. “Our model is unchanged and our one-year target remains $54.”...